Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $629 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases. |
In vitro | Abelacimab prolonged clotting time and decreased human plasma thrombin levels in a concentration-dependent manner over a concentration range of 0.0001 to 1 μM. [1] |
In vivo | Subcutaneous injections of 3-30 mg/kg Abelacimab , days 1, 85, and 114, demonstrated potent and long-lasting anticoagulant effects in crab-eating monkeys, significantly prolonged the aPTT, and had a favorable safety profile, with no significant signs of toxicity or bleeding observed. In addition, intravenous, 0.6 mg/kg Abelacimab also demonstrated excellent anticoagulant activity in the FXI-/- C57BL/6 mouse model of ferric chloride-induced thrombosis, preventing carotid artery occlusion. [1] |
Alias | MAA868, MAA 868 |
Cas No. | 2098724-83-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.